🚀 Dreaming of a career where you can make a difference? Discover the endless possibilities at NIAID with our #recruitment video. Whether you’re passionate about science, administration, or innovation, there is a place for you. Learn more from some of the dedicated public servants who make NIAID a great place to work: https://lnkd.in/e-sD2kX5 #PSRW #NIAIDCareers
National Institute of Allergy and Infectious Diseases (NIAID)
Government Administration
Rockville, Maryland 43,189 followers
Join NIAID and make a difference!
About us
This is the official LinkedIn account for the National Institute of Allergy and Infectious Diseases (NIAID). NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. Posted comments and images do not necessarily represent the views of NIAID, NIH. Comment Policy: www.niaid.nih.gov/global/comment-policy Privacy Policy: www.niaid.nih.gov/privacy Website: www.niaid.nih.gov
- Website
-
http://www.niaid.nih.gov
External link for National Institute of Allergy and Infectious Diseases (NIAID)
- Industry
- Government Administration
- Company size
- 1,001-5,000 employees
- Headquarters
- Rockville, Maryland
- Type
- Government Agency
Locations
-
Primary
9000 Rockville Pike
Rockville, Maryland 20892, US
Employees at National Institute of Allergy and Infectious Diseases (NIAID)
-
Gail Potter
Deputy Section Chief, Clinical Trials Research Section, at National Institute of Allergy and Infectious Diseases (NIAID)
-
Rodolfo Alarcon
Program Officer at National Institutes of Health/National Institute of Allergy and Infectious Diseases
-
Dave Chen
Senior Visualization Scientist at National Institute of Allergy and Infectious Diseases (NIAID)
-
Michael Mullins
Updates
-
Scientists have known for decades that malaria infection is associated with high levels of autoantibodies—antibodies that are associated with autoimmune disorders like systemic lupus erythematosus (SLE). In a recent paper, NIAID researchers and their colleagues examine the molecular mechanisms of these autoantibodies, and show how the autoantibodies which are associated with SLE today could once have served a purpose as a defense against malaria. Learn more: https://go.nih.gov/O2rTs4a
-
-
In the July 3, 2024 NIAID Funding News, read a summary of the June meeting of NIAID’s Advisory Council, including newly approved Council concepts. Explore funding for data reuse and research on adverse effects from toxic chemical exposure. Catch up on key presentations from a recent meeting of NIH’s Advisory Committee to the Director. Share feedback on public engagement in clinical research. Know how to locate a grants management specialist when you need help. Plus, get our answers to reader questions about consultant role classification and NIH’s relationship to CDC and FDA. Learn more at https://go.nih.gov/kaIgJ6b
-
-
Join us on August 8 for the annual SCIP Open House-Rivers of Knowledge. This hybrid event will include sessions on scientific research, career development, training opportunities, and hands-on educational projects. Learn more about SCIP and register for the event at https://go.nih.gov/2YEn9Ya #NIAIDRML
This content isn’t available here
Access this content and more in the LinkedIn app
-
#NIAID scientists learned why some people receiving #cancer treatments called Bruton’s tyrosine kinase (BTK) inhibitors develop infections caused by Aspergillus fungi. The BTK pathway, which is blocked by the treatment, plays a crucial role in providing #antifungal immunity. The scientists say this finding may lead to improved care for people receiving BTK inhibitors. The findings were published in the Journal of Clinical Investigation. Learn more at https://lnkd.in/eDP9yQ4m National Cancer Institute (NCI) Memorial Sloan Kettering Cancer Center Image Credit: CDC
-
-
A Phase 1 trial of an experimental nasal COVID-19 vaccine is now enrolling healthy adults at three sites in the United States. This is the first time that the vaccine, which was designed and tested in pre-clinical studies by scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID), is being tested in people. The candidate vaccine could provide enhanced breadth of protection against emerging virus variants. Learn more: https://go.nih.gov/VKcDfTa #NIAID #COVID #vaccine
-
-
A team of #NIH-funded researchers is making news for their groundbreaking research on T-cell therapies. Learn more about the gene mutation that makes T cells more efficient at treating solid tumors and how sharing scientific data can enable researchers to build on their discoveries in this article from #NIAIDDataScience Dispatch: https://go.nih.gov/7IEpuOQ
-
-
Camila Odio, clinical research fellow and principal investigator of a dengue vaccine trial, describes NIH as a place full of opportunities. After completing a year of research at #NIAID during medical school, Camila returned to NIAID for her fellowship in infectious diseases and now leads a vaccine trial focusing on immune response in people with and without previous dengue exposure. In this video, Camila highlights the invaluable resources and collaborative spirit she has experienced during her time at NIAID. Learn more about her experience and what it’s like to lead a clinical trial at https://go.nih.gov/VjDIcSY. #MeetTheStaff #NIAIDTraining #NIAIDCareers #VaccineResearch
-
#NIAID-supported researchers developed a humanized mouse model that more closely recreates the human immune system, overcoming significant limitations present in older models, particularly regarding antibody responses. These mice provide a new way to study the human immune system, develop novel vaccines and therapeutics, and understand autoimmune disease. The development and evaluation of the model were summarized in Nature Immunology. Learn more: https://lnkd.in/eD3bw8Hk #NIH #immunology UT Health San Antonio
A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses - Nature Immunology
nature.com
-
June 27 is National #HIV Testing Day. The 2024 theme “Level up your self-love: check your status.” reminds people to get tested & know their status. NIH-sponsored research is exploring how pharmacies can increase access to HIV testing. Learn more: https://go.nih.gov/IjmhtPi #NHTD
-